Earnings Alerts

Chemed Corp (CHE) Earnings Fall Short: Q2 Adjusted EPS and Revenue Miss Estimates

  • Chemed’s second-quarter adjusted EPS was reported at $4.27, missing estimates, which stood at $5.24.
  • This indicates a decrease compared to the previous year’s EPS of $5.47.
  • The company’s service revenue increased by 3.8% year-over-year to $618.8 million.
  • Despite this increase, service revenue fell short of the expected $628.8 million.
  • Current analyst recommendations include 3 buys and 1 hold, with no sell ratings.

Chemed Corp on Smartkarma

Analysts at Baptista Research on Smartkarma have been closely monitoring Chemed Corp, a company showcasing a dynamic performance in diverse markets. In their report titled “Chemed Corporation: Expansion into New Markets & New Locations For A Competitive Edge!”, the analysts highlight the impressive first-quarter results of 2025. Particularly, Chemed’s VITAS Healthcare unit demonstrated robust growth, with a 15.1% surge in net revenue to $407.4 million driven by increased days of care and higher Medicare reimbursement rates.

Furthermore, in another report titled “Chemed Corporation: The Covenant Health Acquisition Is A Game-Changing Move!”, Baptista Research sheds light on Chemed’s strategic moves. Despite mixed financial results in the fourth quarter of 2024, Chemed’s hospice segment, VITAS Healthcare, continued to perform well. The acquisition of Covenant Health played a pivotal role in this success, contributing significantly to the quarter’s positive outcomes. These insights from top independent analysts provide valuable perspectives for investors considering Chemed Corp‘s potential.


A look at Chemed Corp Smart Scores

FactorScoreMagnitude
Value2
Dividend2
Growth4
Resilience4
Momentum2
OVERALL SMART SCORE2.8

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Chemed Corp, with its overall Smartkarma Smart Scores, presents a promising long-term outlook for investors. The company’s emphasis on Growth and Resilience, with scores of 4 in both categories, highlights its potential for sustainable expansion and ability to withstand market challenges. These factors indicate a strong foundation for future profitability and development.

While Chemed Corp may not score as high in Value, Dividend, and Momentum, with scores of 2 in each category, its solid performances in Growth and Resilience suggest a positive trajectory. With a foothold in the healthcare field through Vitas Healthcare Corporation, along with its presence in repair and maintenance services, the company exhibits diversification and potential for continued growth in various sectors.

### Summary: Chemed Corporation operates in the healthcare field through its subsidiary Vitas Healthcare Corporation. The Company also maintains a presence in the residential and commercial repair-and-maintenance-service industry under the names Roto-Rooter and Service America Network Inc. ###


Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

πŸ’‘ Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • βœ“ Unlimited Research Summaries
  • βœ“ Personalised Alerts
  • βœ“ Custom Watchlists
  • βœ“ Company Analytics and News
  • βœ“ Events & Webinars